FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH) SCLERODERMA WILL NOT TAKE MY SMILE – World Scleroderma Day 2017 Scleroderma app – now available for download Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease